David Bhatt

David Bhatt investigates PI3K delta isoform signaling in B-cell malignancies and the clinical development of PI3K delta inhibitors. His research has characterized the preferential expression and activity of PI3K delta in B lymphocytes and its critical role in B-cell receptor signaling, survival, and proliferation. He has contributed to clinical investigation of idelalisib and other PI3K delta inhibitors in chronic lymphocytic leukemia and follicular lymphoma, advancing understanding of their efficacy and immune-mediated toxicity profiles. His translational work addresses strategies to manage inflammatory toxicities and overcome resistance to PI3K delta-targeted therapy.